PCN108 NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN
Abstract
Authors
M. Presa A. Soria I. Oyagüez E. Espinosa M. Echave A. Berrocal J.L. Manzano J. Suarez Rodriguez C. Polanco Sánchez